DBS: “We are moving past the idea that one treatment fits all”
sponsored by Medtronic
Author: MedtronicPublished: 26 November 2020
Prep: Cook: Serves:
A deep brain stimulation device – launched by global medical technology company Medtronic – continuously records patients’ brain signals and creates a “diary of motor symptoms”. Two experts share how the technology is introducing a new era of personalised Parkinson’s treatments
“New technologies are very important to further increase the benefit of deep brain stimulation,” says Maria Fiorella Contarino (pictured above), a neurologist based in the Netherlands.
For two decades, Dr Contarino has worked in the field of deep brain stimulation (DBS) – a surgical procedure in which electrodes are placed in specific regions of the brain to treat movement disorders like Parkinson’s.
Using traditional DBS technology, clinicians can measure the activity of a patient’s brain cells during surgery or in clinical settings – and set a frequency and amplitude to stimulate the patient with, 24 hours a day. A new wave of technology launched earlier this year – including the Percept™ PC neurostimulator with BrainSense™ technology – aims to tailor this treatment to the needs of individual patients by continuously recording brain signals in any setting.
“What’s new now with the Percept™ PC neurostimulator is that you can get the same information from the patient at home, and not only in an experimental setting. This opens up the possibility of collecting huge amounts of data – and this is very much needed because all the patients are different,” says Dr Contarino. “There is a chance for both the neurologists and the patients to peek inside the brain, see what the signature mark of the disease is, and how deep brain simulation can change and improve it.”
Created by global medical technology company Medtronic, the Percept™ PC neurostimulator also comes with a Patient Programmer – a handheld device that allows users to control their stimulators and record any changes in brain activity. So far, Dr Contarino has implanted the new neurostimulator into two patients.
“Physicians can use it in two ways,” she explains. “One is when the patient is present in the office, enabling the physician to check what the brain signals are at that moment and adjust the simulation settings accordingly. The second way is via at-home recording, when we switch the recordings on, and the patient goes home. We can then record signals for weeks, so, when the patient returns to the office, we potentially have a sort of diary of the motor symptoms. Based on this information, we could then decide whether the stimulation parameters are good or not.”
Tailoring treatment to a single patient
“These types of technologies are new for nearly everyone,” says Gaetano Leogrande, a senior research and development engineer who helped develop the technology behind the Percept™ PC neurostimulator – BrainSense™.
Leogrande supports healthcare practitioners like Dr Contarino to understand and use the BrainSense™ technology, offering training and answering any questions.
In the future, Leogrande says, it is hoped that the stimulation will be adaptive. This means that the stimulation will be “automatically and frequently adapted according to the needs of a specific patient at a specific point in time”.
“This is important because we hope that it will reduce symptom fluctuations, reduce side effects and extend the longevity of the device, so we won’t have to bother the patient with as many replacement sessions,” he explains.
Tailoring DBS to the needs of each patient is necessary because “every patient has a different form of the disease”, says Dr Contarino. “There are some patients who have more tremors, some who are slower, some with symptoms that are more on one side of the body […] There are patients of all ages – young and old. And, even within the same patient, symptoms can change as the disease progresses.”
With the Percept™ PC neurostimulator, she says: “We are moving past the idea that one treatment fits all. Of course, traditional stimulation gives a consistent and significant improvement to all the patients1, but maybe if we can further tailor the treatment to a single patient or even to a single day of that patient’s life, we can improve it even more.”
Gaetano Leogrande is a senior research and development engineer at Medtronic.
A generational step for DBS
Discussing the response to the technology so far, Leogrande says: “Clinicians seem to be very excited about the technology, the information it provides, and the ease of use. Recently the technology was defined as a game changer by one of the main opinion leaders in this field, because it provides data that cannot be obtained in other way.”
According to Dr Contarino, it’s too early to comment on the advantage of this new system for her patients, but she does say “they’re happy that there is ongoing research and technical advances into the DBS treatment”.
Looking ahead to future developments for the Percept™ PC neurostimulator, Dr Contarino says: “The next step is to study the brain further and try to get more data – and then try to automatize the adaptive stimulation. We want to teach the system to recognise the signals and to set up the best parameters automatically. This will be a big improvement.”
Leogrande adds: “The age of the world’s population is increasing, and it means we can expect more and more people to need these therapies and solutions – so we cannot stop research in understanding how to better care for these patients. My personal belief is that in a few years from now, we’ll be able to collect enough data with this device to use artificial intelligence to predict the evolution of Parkinson’s. This might really be a generational step for the understanding of the brain and the titration of DBS.”
Medtronic’s Percept™ PC neurostimulator with BrainSense™ technology.
At a glance: benefits of the Percept™ PC neurostimulator
It can continuously sense and record brain signals, allowing clinicians to track patient-specific signals and correlate these with patient-recorded events
It’s the only DBS system that is compatible with 3T full-body MRI scans*, meaning it can be left on with certain stimulation configurations while the scans take place
It incorporates low pulse width, providing expanded stimulation options
It has improved battery longevity** and a comfortable new shape
It has an enhanced Patient Programmer*** through a custom-configured Samsung mobile device, allowing patients to manage their therapy more easily.
Need to know
Maria Fiorella Contarino is a neurologist who works at Haga Teaching Hospital and Leiden University Medical Centre, the Netherlands. Her main field of interest is movement disorders and, in particular, advanced treatments for Parkinson’s disease, such as deep brain stimulation. She has worked in the field of deep brain stimulation surgery for more than 20 years.
Gaetano Leogrande is a senior research and development engineer at the Medtronic Bakken Research Centre in the Netherlands. For eight years, he has worked in the field of deep brain stimulation and its application for Parkinson’s disease, essential tremor, dystonia and obsessive-compulsive disorders. As part of his role at Medtronic, he supports healthcare practitioners to better understand and use the Percept™ PC neurostimulator.
Brief Statement: See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
Disclaimer: Information contained herein does not replace the recommendations of your healthcare professional. See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your Health Care Professional.
* Medtronic DBS systems are MR Conditional, which means they are safe for MRI scans only under certain conditions. If the conditions are not met, the MRI could cause tissue heating, especially at the implanted lead(s) in the brain, which may result in serious and permanent injury or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems for a complete list of conditions: http://professional.medtronic.com/mri
**Compared to Activa™ PC device. For median energy use in DBS for patients with Parkinson’s disease, with equivalent settings and no BrainSense™ technology usage
***Compared to the 37642 DBS Patient Programmer for use with Activa™ devices
This article is sponsored by Medtronic. The information in this article is given for information purposes only and does not represent an endorsement by the European Parkinson’s Disease Association of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Don’t worry, be happy! Finding spiritual relief from Parkinson’s
Love, fulfilment and altruism have the power to reduce symptoms
6 days ago
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”
Could a specialised smartwatch support people with Parkinson’s disease?
A specialised smartwatch, which could help those living with Parkinson’s to better manage their condition, will be rolled out to thousands of people in England. The Parkinson’s Kinetigraph, developed by the National Health Service (NHS) in Plymouth and the University of Plymouth, UK, contains sensors designed to monitor the wearer’s activity and buzz with medication reminders. Data collected from the watch – which detects excessive movement, immobility and sleep disturbances – is shared with healthcare providers, allowing for improvements to physiotherapy and prescriptions based on patient needs. Commenting on the smartwatch’s launch, NHS England chief executive Amanda Pritchard said: “Not only is it better for these people living with Parkinson’s, but it is also more efficient for the NHS, freeing up space and time in hospitals for our hard-working staff.” UK health secretary Sajid Javid, meanwhile, described the Kinetigraph as a “fantastic example of how technology is driving cutting-edge innovation…